Jim Sullivan Email

Chief Scientific Officer . enGene

Current Roles

Employees:
78
Revenue:
$12.1M
About
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others. enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.
enGene Address
4868 Rue Levy
St-Laurent, null
enGene Email

Past Companies

enGeneChief Scientific Officer
Translate BioSenior Vice President, Pulmonary Discovery
Sana Biotechnology, Inc.Executive Director, Head of Translational Biology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.